The EU IVDR Class C deadline is 26 May 2026. It is not next quarter. It is now. If you manufacture in vitro diagnostic (IVD) medical devices in the Middle East and Gulf region and hold ambitions for the EU market, this date should be at the top of your compliance calendar. The opportunity to prepare is narrowing fast, and the combination of regulatory requirements, Notified Body (NB) capacity constraints, and technical preparation timelines means every week of delay carries real commercial risk.
The Middle East IVD market by numbers
USD 2.9bMiddle East IVD Market Size 2024 valuation -Healthcare market analytics | 8.4%Projected Annual Growth Rate CAGR 2024–2029 driven by UAE, KSA and Egypt | 40%+Growth in EU-bound Medical Exports GCC manufacturers targeting European certification, 2023–2025 |
90%IVDs Requiring NB Involvement Under IVDR vs. only ~20% under the old IVDD directive | 5 yrsCertificate Validity With ongoing annual surveillance and post-market follow-up | 3Transition Deadlines May 2025, 2026, 2027 -phased by device class |
Why the IVDR matters more than the IVDD ever did
The In Vitro Diagnostic Medical Device Regulation (EU 2017/746) -the IVDR -replaced the old In Vitro Diagnostic Directive (IVDD) and represented a seismic shift in how the EU governs diagnostic devices. For Middle East manufacturers, understanding the gap between the two regimes is not academic. It determines whether you can legally sell into the EU market.
Five critical changes that redefine compliance:
- Expanded product scope: The IVDR captures significantly more products as IVDs than the IVDD. Products previously outside regulatory scope may now require conformity assessment. If your portfolio classification has not been reviewed since 2017, it is almost certainly out of date.
- Four-tier risk classification: Class A (lowest risk) through Class D (highest). The jump in third-party NB involvement is dramatic: under the IVDD, roughly 80% of devices were self-certified. Under the IVDR, over 90% require NB assessment.
- Stricter NB oversight: Notified Bodies must now conduct more rigorous technical documentation reviews, demand stronger clinical evidence, and carry out enhanced performance evaluation assessments against the IVDR's Annex IX or Annex XI pathways.
- Post-market surveillance as a continuous obligation: Certification does not end at issuance. IVDR compliance requires periodic surveillance, post-market clinical follow-up, sampling and testing throughout the five-year certificate lifecycle.
- UDI and EUDAMED transparency: The Unique Device Identification system and the European Database on Medical Devices create a level of product traceability and public accountability that simply did not exist under the IVDD.
The three deadlines - Where does your device sit?
Transition to the IVDR has been phased by device class. Here is the complete picture:
| Deadline | Applies to | Status |
| 26 May 2025 | Devices covered by an IVDD certificate + Class D self-declared devices | PASS |
| 26 May 2026 | Class C devices previously self-declared under the IVDD [APPLICATION REQUIRED NOW] | Critical |
| 26 May 2027 | Class B devices and Class A sterile devices previously self-declared under the IVDD | Upcoming |
Critical additional requirement often missed
Beyond submitting your formal NB application, you must sign a written agreement with your chosen Notified Body within four months of the relevant deadline. An IVDR-compliant Quality Management System ISO 13485 is the established benchmark - must also be in place at the time of application. These are not sequential steps. They must be progressed in parallel.
The notified body capacity problem: The hidden bottleneck
One of the least-discussed challenges in IVDR transition is pure capacity. Demand for IVDR conformity assessments across Europe has significantly outstripped available NB bandwidth. Many manufacturers with otherwise compliant technical files have found themselves in backlogs stretching months beyond their deadline, not because of deficiencies, but because their NB could not schedule the work.
19 Active IVDR Notified Bodies across the EU
As of Q1 2026 -compared to 80+ under the IVDD, creating severe bottlenecks industry-wide (European Commission NANDO database).
For Middle East manufacturers entering the process now, NB selection is as strategically important as technical preparation. Choosing an NB with demonstrated capacity, technical scope matching your device type, and a track record of efficient throughput is not a secondary consideration. It determines your time to market.
How SGS supports your IVDR compliance journey
SGS is one of the largest designated IVDR Notified Bodies in the EU, operating as NB 1639 in Belgium for both the IVDR and the EU Medical Device Regulation (MDR). Critically, our dedicated IVD team currently has capacity and technical expertise to take on new projects -including structured NB transfers from bodies where backlogs are creating compliance exposure.
Device categories we certify:
- Immunogenetics and genetics of cancer and inherited conditions
- Cancer and infectious disease markers
- Clinical biochemistry and other general analytes
- Sterile IVDs
- In vitro diagnostic medical device software (IVD MDSW)
- Self-tests and near-patient tests
Building a multi-market compliance strategy from the Middle East
For GCC and wider Middle East manufacturers, EU certification rarely sits in isolation. The most efficient manufacturers treat IVDR compliance as part of a broader multi-jurisdictional strategy. SGS is uniquely positioned to support this:
| Accreditation | Covers | Scope |
| NB 1639 (Belgium) | EU market –IVDR, MDR and Software as a Medical Device (SaMD) | IVDs + Medical Devices |
| Approved Body 0120 | UK market -UKCA mark | Post-Brexit UK access |
| MDSAP Approved Auditing Org. | US, Canada, Brazil, Australia, Japan | Single audit, 5 markets |
Five steps to take right now
- Confirm your IVDR device classification. Do not assume your IVDD classification transfers unchanged. The IVDR rules reclassify many devices upward in risk tier.
- Audit your QMS for IVDR compliance. ISO 13485 certification is the established benchmark. If your QMS was built around IVDD requirements, it will need updating.
- Assess your technical documentation. Technical files under IVDR are more demanding - particularly around performance evaluation reports and clinical evidence requirements.
- Engage a Notified Body immediately. Selection, scoping, formal application and the subsequent NB agreement all take time. Waiting is not a neutral option.
- Plan your ongoing surveillance program. IVDR certification is a continuous obligation. Build post-market surveillance, annual reporting and renewal planning into your operational framework now.
The IVDR is not a future challenge for Middle East IVD manufacturers. It is a present one. The May 2026 Class C deadline has arrived, and the commercial and regulatory costs of delay compound with every passing week. SGS has the capacity, the accreditations and the Middle East expertise to support you through initial scoping, certification, surveillance and multi-market expansion.
Stay informed. Subscribe now.
For exclusive insights on management systems, ISO standards and sustainable business growth, subscribe to our monthly email newsletter.
About SGS
SGS is the world’s leading Testing, Inspection and Certification company. We operate a network of over 2,500 laboratories and business facilities across 115 countries, supported by a team of over 100,000 dedicated professionals. With more than 145 years of service excellence, we combine the precision and accuracy that define Swiss companies to help organizations achieve the highest standards of quality, compliance and sustainability.
Our brand promise – when you need to be sure – underscores our commitment to trust, integrity and reliability, enabling businesses to thrive with confidence. We proudly deliver our expert services through the SGS name and a portfolio of trusted specialized brands, including Applied Technical Services, Brightsight, Bluesign and Nutrasource.
SGS is publicly traded on the SIX Swiss Exchange under the ticker symbol SGSN (ISIN CH1256740924, Reuters SGSN.S, Bloomberg SGSN SW).
SGS Building, Street no. N 203,
Jebel Ali Free Zone, P.O. Box: 18556,
Dubai, United Arab Emirates